Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Paraganglioma 1Neuroendocrine Tumors 1Insulinoma 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

Trastuzumab 2tipifarnib 1Sorafenib 1Salts 1Oxaliplatin 1Octreotide 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Everolimus 1Disulfides 1Bevacizumab 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Vipoma × Salts × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡